Creating a Patient Trial Community
When TJ Sharpe was diagnosed with Stage 4 melanoma in August 2012, his future looked bleak. He was 37 years old with two young children, the median lifespan for patients with his diagnosis was 18 months and treatment options were limited.Thanks to some knowledge of the pharmaceutical industry he soon realised his best chance of survival was to find a clinical trial. It was a daunting prospect, but his resolve was solid and, after undergoing six surgical operations and four immunotherapy treatments across two different clinical trials, he lived to tell the tale.“I was lucky,” says Sharpe, “I was aware of clinical tria...
Source: EyeForPharma - August 13, 2019 Category: Pharmaceuticals Authors: Katie Osborne Source Type: news
Bristol-Myers releases mixed Opdivo lung cancer results
Bristol-Myers Squibb Co released mixed results on Wednesday from trials testing the survival benefit of its immunotherapy Opdivo in combination with either chemotherapy or its other immuno-oncology drug, Yervoy, as an initial treatment for advanced lung cancer. (Source: Reuters: Health)
Source: Reuters: Health - July 24, 2019 Category: Consumer Health News Tags: healthNews Source Type: news
ipilimumab (Yervoy)
Title: ipilimumab (Yervoy)Category: MedicationsCreated: 6/21/2019 12:00:00 AMLast Editorial Review: 6/21/2019 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - June 21, 2019 Category: Drugs & Pharmacology Source Type: news
Dr. Hussein Tawbi on Efficacy and Safety Results From the CheckMate 204 Melanoma Trial
Cancer Network spoke with Hussein Tawbi, MD, PhD, of MD Anderson Cancer Center, about the efficacy and safety of the combination of nivolumab plus ipilimumab in patients with symptomatic melanoma brain metastases. (Source: CancerNetwork)
Source: CancerNetwork - June 19, 2019 Category: Cancer & Oncology Authors: Hussein Abdul-Hassan Tawbi, MD, PhD Source Type: news
Dr. Ahmad Tarhini on Ipilimumab vs Interferon- α2b for Resected High-Risk Melanoma
Cancer Network spoke with Ahmad Tarhini, MD, PhD, about the results of the phase III United States Intergroup E1609 trial, presented at ASCO 2019. (Source: CancerNetwork)
Source: CancerNetwork - June 12, 2019 Category: Cancer & Oncology Authors: Ahmad A. Tarhini, MD, PhD Source Type: news
Do Brain Metastases Rule Out Immunotherapy in RCC?
An interim analysis of the CheckMate 920 phase IIIb/IV trial evaluated nivolumab plus ipilimumab in advanced renal cell carcinoma patients with brain metastases. (Source: CancerNetwork)
Source: CancerNetwork - June 11, 2019 Category: Cancer & Oncology Authors: Jim Kling Source Type: news
Study Finds Modest Reality of Immunotherapy for Cancer
This study quantifies the disturbing trend that, despite the expansion in the number of patients eligible for expensive and potentially toxic ICIs [immune checkpoint inhibitors], the ratio of those benefiting is decreasing,” wrote Dr. Daniel V.T. Catenacci, co-author of an editorial that accompanied the study in JAMA Network. “Observations in this article are sobering and remind us to keep expectations realistic.”
Both Catenacci and Haslem agreed that the study should serve as a reminder to patients, physicians and policy makers to have more realistic discussions about the use of, and expectations of, these immunothe...
Source: Asbestos and Mesothelioma News - June 6, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news
ILLUMINATE 301 Will Study Experimental Immunotherapy for Patients With Advanced Melanoma
Investigators are now enrolling for a phase III trial testing the experimental immunotherapy tilsotolimod plus ipilimumab in patients with advanced melanoma who have progressed on anti –PD-1 therapy. (Source: CancerNetwork)
Source: CancerNetwork - June 4, 2019 Category: Cancer & Oncology Authors: Lauren M. Dembeck Source Type: news
KEYNOTE-029: Alternate Doses of Ipilimumab Show Similar Results in Advanced Melanoma
Researchers tested standard-dose pembrolizumab plus ipilimumab at 50-mg or 100-mg doses in patients with previously untreated advanced melanoma. (Source: CancerNetwork)
Source: CancerNetwork - June 4, 2019 Category: Cancer & Oncology Authors: Lauren M. Dembeck Source Type: news
Combination checkpoint blockade effective in pre-surgical setting for early-stage lung cancers
(University of Texas M. D. Anderson Cancer Center) Neoadjuvant, or pre-surgical, treatment with nivolumab plus ipilimumab resulted in an overall major pathologic response (MPR) rate of 33 percent of treated patients with early-stage, resectable non-small cell lung cancers, meaning these patients had less than or equal to 10 percent viable tumor remaining at surgery. With these results, the combination immunotherapy met the pre-specified trial efficacy endpoint of the phase II NEOSTAR trial conducted by researchers at The University of Texas MD Anderson Cancer Center. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 3, 2019 Category: International Medicine & Public Health Source Type: news
Neoadjuvant Immune Checkpoint Inhibitor Combo Promising for NSCLC
Researchers compared the percentage of non-viable tumor and tissue resident memory tumor infiltrating lymphocytes for nivolumab plus ipilimumab vs nivolumab alone. (Source: CancerNetwork)
Source: CancerNetwork - June 2, 2019 Category: Cancer & Oncology Authors: Jim Kling Source Type: news
Nivolumab with ipilimumab: Combination has added benefit in advanced renal cell carcinoma
(Institute for Quality and Efficiency in Health Care) There are advantages in overall survival, which are not offset by any disadvantages of similar importance. Extent of the added benefit depends on the patient risk scores. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 17, 2019 Category: International Medicine & Public Health Source Type: news
CheckMate 204:'Practice-Changing' for Metastatic Melanoma CheckMate 204:'Practice-Changing' for Metastatic Melanoma
The ipilimumab plus nivolumab combination gives patients a reasonable chance of CNS tumor regression, thus not requiring radiation, according to Jeffrey Weber.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 3, 2019 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news
DART: Success Story in High-Grade Neuroendocrine Carcinomas DART: Success Story in High-Grade Neuroendocrine Carcinomas
Patients with high-grade neuroendocrine carcinomas benefit from dual checkpoint inhibition with ipilimumab and nivolumab after single-agent checkpoint inhibition has failed. Is dual checkpoint blockade ready for prime time?Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 2, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Immune checkpoint inhibitor combo efficacious for patients with neuroendocrine carcinoma
(American Association for Cancer Research) A combination of the anti-CTLA-4 immunotherapeutic ipilimumab (Yervoy) and the anti-PD-1 immunotherapeutic nivolumab (Opdivo) showed clinical benefit among patients with rare, high-grade neuroendocrine carcinoma, according to results from the DART phase II clinical trial presented at the AACR Annual Meeting 2019, March 29-April 3. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 31, 2019 Category: Cancer & Oncology Source Type: news
